News | May 21, 2026
Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Cagrilintide represents a novel approach to obesity management
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
